

Hao Hong is currently a Research Assistant Professor of Radiology at the University of Michigan – Ann Arbor, where he shares responsibility for management of Imaging Core at the Center for Molecular Imaging (CMI) of University of Michigan Health Systems. Prior to his arrival at the University of Michigan, Dr. Hong was an Assistant Scientist of Radiology at University of Wisconsin – Madison. Dr. Hong was trained as a biochemist during his PhD research, where he designed series of fluorescent probes for imaging of nitric oxide in the inflammation.

Dr. Hong has gained extensive experience and knowledge in several different areas: biochemistry and molecular biology, radiochemistry, multimodality molecular imaging, nanotechnology, immunology, cancer biology, etc. His current lab at University of Michigan works tirelessly on **1)** Development of novel PET imaging agents for early diagnosis of multiple diseases (in particular cancer); **2)** Monitoring the efficacy of therapeutic intervention; and **3)** Biomedical applications with functionalized nanomaterials. His work has led to the development of molecular probes that have high clinical translational ability for detection of cancer (multiple types) and metastases which express biomarkers such as CD105, tissue factor, or VEGFR.

As an active member of the CASNMMI, SNMMI, and WMIC, Dr. Hong participates actively in the field of PET imaging. He has published over 80 research articles on the topic of molecular imaging in peer-reviewed journals including *Nature Nanotechnology*, *ACS Nano*, and *Journal of nuclear medicine* etc. (H-index = 28; total citations > 2,300), 8 book chapters and co-edited one book with Dr. Weibo Cai from University of Wisconsin. He serves as a reviewer for more than 20 journals including *Journal of Nuclear Medicine, EJNMMI, Journal of the American Chemical Society etc.* and abstracts for the WMIC annual meetings, and he is currently the executive editor of *American Journal of Nuclear Medicine and Molecular Imaging.* At the same time, he has won various awards from different societies, including but not limited to the Susan G. Komen Postdoctoral Fellowship (2009-2011), Berson-Yalow Award from SNMMI (2012), and Young Scientist Awards from CASNMMI (2014).

Position statement: With the field of molecular imaging being increasingly interdisciplinary, synergistic integration of resources and talents will become more critical to promote the whole field. From its established date, CASNMMI continuously serves as a powerful bridge to unite the Chinese brilliant minds for molecular imaging and boost their communications/collaborations. As a junior investigator in molecular imaging, I love to share ideas and work closely with other people so that we can maximize our output and achieve something bigger together. That is why I feel that I share the same goal with CASNMMI, which is to advance the field of nuclear medicine and molecular imaging, especially for the Chinese community.

One of the keys to fully utilize the current resources is to establish effective communication between different researchers. If given the opportunity to serve as a secretary for CASNMMI, I am committed to devoting my energy into helping the President and Board of Directors coordinate affairs inside the society, organizing different activities for the society, lubricating the communication/collaboration between scientists, and attracting new members to CASNMMI.

Dr. **Yubin Miao** received his Ph.D. degree in Radiopharmaceutical Chemistry at Beijing Normal University in 1997, under the mentorship of Professor Boli Liu. He then spent three years to carry out postdoctoral research in Professor Thomas P. Quinn's group at the University of Missouri-Columbia. Dr. Miao was a Research Assistant Professor in the Department of Internal Medicine at the University of Missouri-Columbia from 2003 to 2006. In 2006, he joined the College of Pharmacy as a tenure-track Assistant Professor at the University of New Mexico. From 2006-2014, he served as an Assistant Professor and Tenured Associate Professor in the College of Pharmacy at the University of New Mexico. In 2015, Dr. Miao joined the Department of Radiology at the University of Colorado Denver, where he is a Tenured Associate Professor and Director of Radiopharmaceutical Science.

The research interests in Dr. Miao's laboratory focus on developing novel radiolabeled peptides for cancer (melanoma, breast and prostate cancers) diagnosis and treatment. Specifically, Dr. Miao and his research team are utilizing radiolabeled peptides to target G protein-coupled receptors (GPCRs) that are over-expressed on cancer cells for cancer detection and therapy. Dr. Miao has published 68 peer-reviewed papers and book chapters, and presented 50 invited lectures and 74 abstracts in international and national conferences. Dr. Miao has received a number of prestigious awards including Society of Nuclear Medicine Radiopharmaceutical Science Council Young Investigator Award and American Association of College of Pharmacy New Investigator Award. Dr. Miao sits on the editorial board for *Nuclear Medicine and Biology*, *American Journal of Nuclear Medicine and Molecular Imaging*, *Frontiers in Biomedical Physics* and *Current Molecular Imaging*, and serves as a reviewer for over 20 other journals. Moreover, Dr. Miao has been a member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society of Radiopharmaceutical Sciences (SRS) and Radiopharmaceutical Science Council (RPSC) for more than ten years, and has been actively attending the SNMMI- and SRS-sponsored scientific meetings. Dr. Miao has become a strong advocate of Radiopharmaceutical Sciences.

Platform Statement: Radiopharmaceutical Sciences are the foundations of nuclear medicine and molecular imaging. The training of the next generation of radiopharmaceutical scientists is critical for the growth and advancement of Radiopharmaceutical Sciences. If elected to the CASNMMI Board of Directors, Dr. Miao would enthusiastically support the CASNMMI programs that recognize the accomplishments of new radiopharmaceutical scientists, promote innovative research and provide support to talented graduate students and postdoctoral researchers. Dr. Miao is committed to promote the visibility of the CASNMMI by achieving the goals of the CASNMMI, and support the interests of the current members while developing new strategies to recruit new members.

Yumin Zhang (张裕民), MD, PhD, is a Principal Scientist of Translational Imaging at AbbVie, a pharmaceutical company, split from the renowned Abbott Laboratories. Dr. Zhang received his B.S. and M.S. degrees in Medicine and Nuclear Medicine at the Fourth Military Medical University (第四军医大学), China in 1985 and 1991, and doctorate degree at Peking Union Medical College (北京协和医院) in 1994 under the guidance from Dr. Chien Chou (周前). He practiced as Attending Nuclear Medicine Physician in Xijing Hospital (西京医院) (1994-1996). Subsequently, he worked in St. Bartholomew's Hospital, University of London (1996), and German Cancer Research Center as PET Follow (1997-1999). He moved to the United States by joining University of Massachusetts Medical Center, for developing antisense probes for imaging in vivo hybridization, as research fellow and assistant professor (1999-2003).

He embarked industry for Imaging for Pharmaceutical Development from 2003, by joining Millennium Pharmaceuticals Inc, helped building one of the first Multi-modality imaging center, and he carried his successes to the development of the Translational Imaging Department in Abbott (2006) and AbbVie (2013). He has been focusing on advocating and development "Imaging Guided Molecular Targeted Therapeutics" in the past decade and has made substantial contributions to move early discovery compounds (and antibodies along with antibody-drug conjugates) to clinical development.

He has been an active participant of Chinese American Society of Nuclear Medicine (and Molecular Imaging), and recently has been served as Board member with the role of Secretary and Treasurer since 2013.

Statement: It is a great privilege of being eligible to participate in the election of president-elect of CASNMMI. If I am trusted by the colleagues to be elected, I have good will and confidence to work with the members of BoD and the members of the Society to carry on its success, to make the Society an organization of a combination of sciences, entertainment, information exchange, career-promoting and friendship platform. Thanks for your trust.

Dr. **Zibo Li** obtained his PhD in chemistry from the University of Virginia in 2006. After a postdoctoral position at the Stanford University from 2006-2008, he joined the Molecular Imaging and Biomarker Research division, Siemens Inc as a senior scientist. In Nov 2008, he was recruited as an Assistant Professor at the USC Radiology Department, and established a very productive radiochemistry research program at USC molecular imaging center. In June 2014, Dr. Li relocated to the University of North Carolina-Chapel Hill as an Associate Professor of Radiology and Biomechical Research Imaging Center.

Currently, Dr. Li is the Director of Cyclotron and Radiochemistry Program at UNC-Chapel Hill. His research has been focused on the development and evaluation of novel tools, reagents and methods to image specific molecular pathways in vivo; particularly those that are key targets in disease processes. Within this area of research, Positron emission tomography (PET) has emerged as one of the most powerful clinical imaging technique, because it can provide critical in vivo information on the distribution of radiolabeled biomolecules for non-invasive diagnosis. Dr. Li's research areas include the development of novel labeling methods and imaging PET probes for cancer, diabetes, and cardiovascular disease related research. Dr. Li received numerous prestigious awards including the highly competitive Mark Tetalman Memorial Award from Society of Nuclear Medicine (2011), which honors the research accomplishments of a young investigator who is pursuing a career in nuclear medicine.

Personal statement: Dr. Li has been an active member of CASNMMI for many years. He aims to work closely with other colleagues, industry partners, and Chinese Universities to make CASNMMI a well-organized and well-known platform to promote collaborations, facilitate translational research, educate the public, and finally build a strong Chinese Imaging Society in the States.

Dr. **Kai Chen** is an Assistant Professor of Radiology and an Associate Member of the Norris Comprehensive Cancer Center at the University of Southern California (USC). He currently leads the Molecular Imaging Laboratory of the USC Molecular Imaging Center (MIC) where he is developing novel molecular imaging probes (small molecules, peptides, peptidomimetics, proteins, antibodies, and nanoparticles) for PET, SPECT, MRI, optical imaging, as well as multimodality imaging.

Dr. Chen received a Ph.D. degree in Chemistry from Nankai University, China (2001). He then moved to the United States where he performed his postdoctoral research at Harvard Medical School. In 2005, Dr. Chen joined Siemens Healthcare USA, Inc. as a research scientist, where he led several projects from preclinical discovery to clinical investigation. He was promoted to Group Leader in 2006 and Project Manager in 2008. In the summer of 2009, Dr. Chen moved to the National Institutes of Health (NIH) where he was part of the Intramural Research Program team of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). In 2010, Dr. Chen joined the USC as a faculty member.

Dr. Chen has published over 60 peer-reviewed articles, and he is a co-inventor of 17 International and US patents. He has served as a reviewer for a number of funding agencies. Dr. Chen has also served as an active reviewer for over 50 research journals. In addition, he sits on the Editorial Board of 8 peer-reviewed international journals. Dr. Chen has been an active member of several professional societies including the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the World Molecular Imaging Society (WMIS), and the American Chemical Society (ACS). He is a committee member of the Radiation Safety Committee (RSC) and the Radioactive Drug Research Committee (RDRC) at the USC.

Personal Statement: The CASNMMI offers an outstanding platform of resources, connections, and continuing education for all professionals especially, in the Chinese community, with interest in nuclear medicine and molecular imaging. If elected to the CASNMMI Board of Directors, Dr. Chen hopes to use his experiences in academia and industry setting to enthusiastically find common ground among all types of scientists in our organization, work closely with other colleagues to continue to promote the goals of the CASNMMI, facilitate the translation process of imaging probes into patients' care, train the next generation of nuclear medicine and molecular imaging scientists, and recruit new members to the CASNMMI.